Loading data for CSBR — first visit, this takes a few seconds.

アラート

Champions Oncology Inc. (CSBR)

NasdaqCM: CSBR · リアルタイム株価 · USD

5.09

+0.06 (1.19%)

終値時点： Aug 18, 2026, 3:59 PM

1.19% (1D)

買気配	3.78
時価総額	70.72M
売上高（TTM）	59.42M
純利益（TTM）	-1.18M
ベータ	0.41
EPS（TTM）	-0.08
PER（TTM）	n/a
予想PER	50.9
PBR（TTM）	17.92
PSR（TTM）	1.19
Earnings Date	Dec 14, 2020

売気配	6.74
出来高	10,864
平均出来高（20日）	9,250
始値	5.24
前日終値	5.03
当日レンジ	5.04 - 5.33
52週レンジ	4.88 - 8.74
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CSBRについて

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug deve...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Feb 2, 2007

従業員数 214

上場取引所 NasdaqCM

ティッカー CSBR

ウェブサイト https://www.championsoncology.com

企業情報の全文

業績

2026年のChampions Oncologyの売上高は59.42Mで、前年の56.94Mから4.36%の増加でした。利益は-1.18Mで、-124.99%の減少でした。

財務諸表

決算サプライズ

Champions OncologyはDec 15, 2025に四半期決算を発表しました：

売上高は $13.84M で、予想を下回りました $0, うち 11.98% の前年比増加にあたります.

EPSは 0.06 で、予想を下回りました , うち 20.00% の前年比増加にあたります.

次回決算発表

Champions Oncology Inc.の決算発表予定日は Dec 14, 2020, 引け後の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2週間前 · Zacks

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.

2週間前 · GuruFocus.com

Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...

Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue.

3週間前 · MarketBeat

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or...

3週間前 · Zacks

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

3週間前 · Zacks

2 Microcaps With Gross Margin Catalysts

CSBR and CEPL have levers in place for Gross Margin improvement.

2ページ中1ページ

Champions Oncology Inc. (CSBR)